中低收入国家孕产妇干预警戒协调:利益相关方会议报告
比尔及梅琳达·盖茨基金会于2018年5月1-2日在阿姆斯特丹召开全球专家会议,讨论基于整合的孕产妇干预警戒(MIV)系统的孕期疫苗药物警戒框架。会议确定了五项优先行动,包括建立背景率、识别哨点监测点、开发数据共享能力、制定指南与方案以及准备沟通与风险管理计划。
要点
- 多种新疫苗(如呼吸道合胞病毒、B组链球菌疫苗)正针对孕妇适应症进行临床开发。
- 中低收入国家需建立MIV系统以实现新孕产妇疫苗的同步引入和安全监测。
核心结论
- 整合MIV于常规产科和新生儿保健 continuum 及相关项目和数据系统,可从根本上改善孕产妇、新生儿和儿童健康。
研究设计与样本
- 比尔及梅琳达·盖茨基金会于2018年5月1-2日在阿姆斯特丹召集全球专家会议,形成利益相关方会议报告。
主要发现
- 多种新疫苗正针对孕妇适应症进行临床开发,如呼吸道合胞病毒疫苗和B组链球菌疫苗。
关键数值与推荐
- 会议确定的优先行动包括:建立背景率以更好评估新出现的安全信号和疫苗有效性;识别潜在哨点疫苗监测点;开发数据共享能力;制定指南文件和方案;提前准备文化适宜的沟通计划和风险管理计划。
临床怎么用
- 规划MIV需要多学科协作方法,充分利用并建立在现有资源基础上,并在需要处建设新能力和容量。
- 改进的孕期药物警戒平台可加强其他疫苗和药品安全系统,并提高中低收入国家的母婴研究能力。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Although major reductions in maternal and child mortality were achieved in the Millennium Development Goals era, progress must be accelerated to meet Sustainable Development Goals health targets by 2030. An estimated 2.7 million neonatal deaths and 2.6 million stillbirths still occur annually. Over the past several years there has been renewed global interest in innovative approaches to maternal immunization to potentially decrease mortality and severe morbidity in neonates, and in the pregnant woman and her fetus. Several new vaccines are in clinical development for indications in pregnant women, e.g., vaccines against respiratory syncytial virus, and group B streptococcus. Achieving near-concurrent introduction of new maternal vaccines in high-, middle-, and low-income countries requires that mechanisms are in place for appropriate safety monitoring worldwide. The Bill & Melinda Gates Foundation convened a global expert meeting in Amsterdam on May 1-2, 2018, to discuss a framework for appropriate pharmacovigilance for vaccines used during pregnancy based on integrated maternal interventions vigilance (MIV) systems and collection of appropriate data to inform timely decision-making by and for pregnant women. Planning for MIV requires a multi-disciplinary, collaborative approach that fully leverages and builds upon existing resources, and builds new capabilities and capacity where needed. Meeting participants identified priority actions including (1) establishing background rates to better evaluate emerging safety signals and vaccine effectiveness, (2) identifying potential sentinel vaccine surveillance sites, (3) developing data sharing capabilities, (4) creating guidance documents and protocols, and (5) the advanced preparation of culturally-appropriate communication plans and risk management plans. Integrating MIV across the routine obstetric and neonatal health care delivery continuum and all relevant programs and data systems could result in fundamental improvements in maternal, neonatal and child health. Improved pregnancy pharmacovigilance platforms may strengthen other vaccine and drug product safety systems and improve maternal and child research capabilities in LMICs.
引用
- Sobanjo-Ter Meulen A, Munoz FM, Kaslow DC, et al. Maternal interventions vigilance harmonization in low- and middle-income countries: Stakeholder meeting report; Amsterdam, May 1-2, 2018. Vaccine. 2019. PMID: 30955981. doi:10.1016/j.vaccine.2019.03.060
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。